Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile, a common hospital-acquired infection. Fecal microbiota transplantation's success as a therapy for C. difficile has inspired interest in performing clinical trials that experiment with fecal microbiota transplantation as a therapy for other conditions like inflammatory bowel disease, obesity, diabetes, and Parkinson's disease. Results from clinical trials that use fecal microbiota transplantation to treat inflammatory bowel disease suggest that, for at least one condition beyond C. difficile, most fecal microbiota transplantation donors produce stool that is not efficacious. The optimal strategies for identifying and using efficacious donors have not been investigated. We therefore examined the optimal Bayesian response-adaptive strategy for allocating patients to donors and formulated a computationally tractable myopic heuristic. This heuristic computes the probability that a donor is efficacious by updating prior expectations about the efficacy of fecal microbiota transplantation, the placebo rate, and the fraction of donors that produce efficacious stool. In simulations designed to mimic a recent fecal microbiota transplantation clinical trial, for which traditional power calculations predict $ 100% statistical power, we found that accounting for differences in donor stool efficacy reduced the predicted statistical power to $ 9%. For these simulations, using the heuristic Bayesian allocation strategy more than quadrupled the statistical power to $ 39%. We use the results of similar simulations to make recommendations about the number of patients, the number of donors, and the choice of clinical endpoint that clinical trials should use to optimize their ability to detect if fecal microbiota transplantation is effective for treating a condition.
Introduction
Fecal microbiota transplantation (FMT), the transfer of stool from a healthy person into an ill person's gut, is a highly effective treatment for recurrent Clostridium difficile infections, which kill 30,000 Americans a year. Despite FMT's efficacy and increasingly widespread use, the biological mechanism by which FMT cures the infection is not fully understood. [1] [2] [3] [4] [5] [6] [7] FMT's success in treating C. difficile has generated interest in experiments that use FMT to treat other conditions related to the gut and the gut-associated microbiota. 8, 9 However, emerging evidence suggests using FMT for these other diseases will be more challenging. Notably, in a recent study by Moayyedi et al. 10 that used FMT to treat ulcerative colitis, patients appeared to respond to stool from only one of the six stool donors. Stool from all other donors was no more efficacious than placebo. These results suggest that the effectiveness of FMT can depend strongly on the choice of stool donor.
Ideally, information collected before or during a clinical trial could be used to identify which donors are efficacious. Predictions about a donor's efficacy could be repeatedly updated depending on that donor's performance, performance of other donors, and prior expectations about donor efficacy and heterogeneity. There is, however, not enough clinical information about this variability or biological information about the mechanism by which FMT treats disease to create or validate a model for any particular indication. We therefore present a general model of differences in donor stool efficacy that is not specific to a clinical indication or biomarker. Using this model, we describe the optimal, adaptive, Bayesian strategy for allocating donors and then formulate a computationally tractable myopic Bayesian allocation heuristic.
Using simulations of clinical trials, we show that differences in donor efficacy and the trial's strategy for allocating donors can have substantial impacts on the trial's statistical power. We compare the performance of nonadaptive approaches for allocating patients to donors against a variation of a previously studied adaptive algorithm (a ''play the winner'' strategy) [11] [12] [13] and our own Bayesian heuristic. We find that, in many cases, traditional nonadaptive allocation strategies are likely to falsely conclude that FMT is inefficacious. Adaptive strategies, however, can substantially increase a trial's ability to detect if FMT is efficacious.
Model of differences in donor stool efficacy
The results of the trial reported in Moayyedi et al. 10 raise the possibility that only some donors produce stool that is efficacious for treating ulcerative colitis, a type of inflammatory bowel disease. This possibility-that donors produce stool that is either efficacious or not-is a special case of a more general model of donor-patient interaction.
In this general model, a patient in the treatment arm can respond to the treatment under one of three scenarios:
. the patient failed to respond to the FMT itself but did respond to the placebo effect;
. the patient responded to the FMT and would have responded to the placebo effect if they had been given only a placebo; or . the patient responded to the FMT and would not have responded to a placebo.
We account for these three possibilities by treating the two effects-an effect from stool and the placebo effect-as independent. Specifically, we say that stool has some ''active ingredient'' that, in the absence of a placebo effect, could cause a patient to respond.
In theory, stool from different donors could have different ingredient efficacies for different patients. Assuming that there are discrete classes of patients and donors, we write the ingredient efficacy of stool from a donor in class d for a patient in class t as p ðt,d Þ ingr . The probability p ðt,d Þ eff that a patient in class t will respond to treatment (i.e. the treatment efficacy) using a donor in class d depends on p ðt,d Þ ingr and the probability p pl that that patient will respond to the placebo effect:
The ''matching'' between patients and donors, if it exists, is not well understood and cannot yet be predicted. Furthermore, to minimize the patients' exposure to unknown pathogens, current FMT trials usually treat each patient with stool from only one donor. Thus, each patient is selected randomly from the different patient classes, so the observed treatment efficacy p ðd Þ eff is actually the expected value of p ðt,d Þ eff over the different patient classes t and patient placebo rates p pl . Let f ðtÞ patient be the fraction of patients that are in class t and f pl be the probability distribution function of the placebo rates so that
Due to this limitation, we will model only the variables p ðd Þ eff , p ðd Þ ingr , and p pl with the understanding that these variables are actually the mean values over distributions of patient characteristics.
The study by Moayyedi et al. 10 suggests that the majority of donors produce stool that has no efficacy beyond placebo, that is, that there is a class of donors for which p ðd Þ ingr ¼ 0. In light of the paucity of the available data about donor qualities, we made a further simplification to the model: we assert that a fraction f eff of donors have ingredient efficacy p ingr 4 0 and the remaining donors have p ingr ¼ 0 (i.e. p eff ¼ p pl ). This final model is summarized in Figure 1 .
Bayesian model formulation
Adaptive donor assignment strategies aim to use the information derived from the patients' outcomes-and possibly some a priori beliefs about the values of the model parameters-to make decisions about how to assign donors. The donor assignment problem, then, is amenable to a Bayesian treatment, which will model the three parameters described above as well as the ''qualities'' q 2 f0, 1g D of the D donors, where q i ¼ 0 indicates that donor i produces inefficacious (i.e. placebo equivalent) stool and q i ¼ 1 indicates that that donor produces efficacious stool.
As described in Section 4, we found that the results of simulations using this model were mostly insensitive to the choice of prior distribution on the parameters ð p pl , p ingr , f eff Þ, so in most cases we used a simple uniform prior on these values. In one set of simulations, we articulated these priors using beta distributions
where the hyperparameters A ðÁÞ and B ðÁÞ can be drawn from prior clinical trial results. We chose to model the prior on p ingr via a beta distribution on p eff because p eff is directly observable in terms of patient outcomes, while p ingr can only be back computed from p eff and p pl via equation (1) . The clinical trial results for Moayyedi et al. 10 and their translation into the model parameters and prior hyperparameters are presented in Table 1 .
We model the prior on the donor qualities q as a function of f eff , the fraction of donors in the general population that are efficacious as Figure 1 . The model of differences in donor efficacy. In the model, donors are efficacious or not. Patients respond to FMT from an efficacious stool donor with probability p eff . An FMT from an inefficacious stool donor is considered identical to a placebo, i.e. patients respond with probability p pl . The fraction of donors in the general donor population that are efficacious is f eff . FMT: fecal microbiota transplantation. The data used to update the priors are the numbers of patients treated successfully and unsuccessfully for each donor. The likelihood of the data X given these parameters is
where Binðs, n; pÞ is the binomial probability mass function with s successes among n total trials with success probability p, s i is the number of patients successfully treated with stool from donor i, and n i is the total number of patients treated with stool from donor i. Combining equations (6) and (7) shows that the posterior probability of the parameters q and
where PðpÞ is the prior. The derivation of the posterior predictive probability of a patient responding to treatment with stool from a given donor is in Appendix 1.
We found no closed-form solution to the integrals required to compute the predictive posterior probabilities, which we instead evaluated using numerical methods. Specifically, we used Monte Carlo integration with SUbregion-Adaptive VEgas (Suave), an important sampling method combined with a globally adaptive subdivision strategy. Sampling for this integral was performed with Sobol pseudo-random numbers. The integrator was implemented in Cþþ using the Cuba package.
14 Wrappers for the integration routine were implemented in Python 3 and simulations were then parallelized to run on multiple cores to optimize computational run time. 15 
Optimal donor allocation
Given the priors on the model parameters and the observed patient outcomes, what is the optimal choice for the next donor? Answering this question requires evaluating the ramifications that a donor choice will have for the next patient as well as for the trial as a whole.
The problem of allocation of patients to donors within the treatment arm is similar to other ''bandit'' problems. 16 In general, bandit problems treat how to allocate patients between the placebo arm and the treatment arm (or arms). Previous clinical trials using FMT for inflammatory bowel disease (IBD) have randomized patients to the placebo and treatment arms in a 1:1 ratio. 10, 17 To remain consistent with this practice, we assume that patients have been allocated equally to the placebo and treatment arms and only study strategies for the allocation of patients to donors within the treatment arm.
Given this constraint, we formulate an optimal donor allocation strategy. Let a trial state be a trial with some set of observed patient outcomes. Given a donor choice, each trial state has two child states: one in which the patient assigned to that donor responded to treatment and one in which the patient did not respond. The optimal donor choice is the one with maximum expected utility U, where the utility reflects the outcome of the entire trial. The utility of a donor choice is
where p is the probability of a patient responding to treatment from that donor, S is the child state with a success from that donor, and F is the child state with a new failed patient. FMT trials are often designed with a patient horizon (i.e. they will terminate after N patients have been treated), and it is natural to associate utilities with the terminal trial states. For example, it would be sensible to take the actions that are most likely to lead to a trial with a significant p-value as measured by frequentist statistics, so every terminal node with a significant p-value would have utility 1 and the others would have utility 0. Different choices for the utility function would be appropriate under different circumstances and would lead to different strategies. Equation (9) shows that the optimal donor choice at a nonterminal trial state depends only on the utility of its child nodes and each donor's probability of a successful treatment given that trial state. Thus, the optimal choice at an intermediate trial state can be found by backward induction:
1. Associate each terminal trial state (i.e. those with N patients treated) with a utility. An algorithm for counting the number of unique trial states as a function of the number N of patients treated, derived in Appendix 1, shows that a moderate-size trial with N ¼ 30 patients in the treatment arm has more than 10 million terminal trial states, making this optimal approach infeasible.
Deterministic myopic allocation heuristic
In light of the intractability of the optimal solution, we formulated a myopic heuristic that, rather than optimizing the expected utility of the entire trial, simply assigns the next patient to the donor that maximizes the probability that that patient will have a successful outcome. At each step in the trial, the predictive posterior probability of a successful patient outcome is computed for each donor, and the donor with the maximum probability is used. (In the case of a tie, a donor is chosen at random.) Because this approach takes action only with respect to the next patient, it was not formulated in terms of the utility of the terminal trial states.
Methods 3.1 Comparison of donor allocation strategies
To evaluate the effectiveness of our myopic heuristic, we performed simulations of clinical trials using four different strategies for allocating patients to donors. The first two strategies, block allocation and random allocation, are nonadaptive. The other two strategies, a randomized urn-based strategy and the myopic Bayesian heuristic, are response adaptive. In each strategy, an equal number of patients were allocated to the treatment and placebo arms. (This equal allocation to the placebo arm was intended to preserve statistical power, which would probably have decreased if the myopic algorithm were allowed to allocate patients away from the placebo arm.) 18, 19 3.1.1 Block allocation In a block allocation, patients are evenly allocated to donors. For example, if there are 30 patients and six donors, the first five patients are treated with the first donor, the second five patients are treated with the second donor, etc. (In clinical practice, patients would be randomized within the blocks.)
Random allocation
In a random allocation, patients are allocated to donors at random. (On average, random allocations are similar to block allocations, so these two types of nonadaptive simulation yield similar results.)
Urn-based allocation
Our urn-based allocation strategy is a variation on the ''play-the-winner'' strategies designed and studied as an ethical 20 and statistically rigorous way to decide how to allocate patients to a treatment arm when a trial includes more than one treatment arm. [21] [22] [23] In this study, we used the generalized Po´lya's urn 24 with parameters w ¼ 1, ¼ 3, ¼ 0, and without replacing the drawn ball.
Myopic Bayesian heuristic
This is the strategy described in the previous section. Except when noted, a uniform prior on the three parameters ð p pl , p ingr , f eff Þ was used.
Simulated clinical trials
The expected fraction of patients allocated to efficacious donors and the statistical power of clinical trials using different donor allocation strategies were estimated using simulated clinical trials. In each simulation, the three model parameters (p pl , p eff , f eff ) and the number of patients in each arm were fixed. The same number of patients was allocated to the placebo and treatment arms. For each combination of the trial parameters, 10,000 lists of six donors each were randomly generated. Donors were designated as efficacious or not efficacious by random chance according to the frequency of efficacious donors f eff . The same donor lists were used for simulations for each of the allocation strategies.
In one set of simulations, the number of donors was varied among 1, 3, 5, 10, 15, and 30. For those simulations, lists of 30 donors were generated for each parameter set and trial iteration. The lists were truncated for the simulations using less than 30 donors.
For each allocation strategy and donor list, a trial was simulated. In each simulation, a patient allocated to an efficacious donor responds to the treatment with probability p eff . Patients allocated to inefficacious donors or to the placebo arm respond with probability p pl . For adaptive allocations, the outcomes from all the previous patients' treatment were determined before the donor for the next patient was selected.
Clinically relevant parameter values
Simulations were performed for all combinations of parameter values selected to reflect clinically relevant possibilities:
1. The placebo rate p pl is either 0.05 (a low placebo rate consistent with stringent, objective outcomes; e.g. endoscopic Mayo score) 10, 17 or 0.25 (a high placebo rate consistent with self-reported, subjective outcomes) 25 
Computing statistical power
After determining the outcome of all the patients in the trial, the p-value of a one-sided Fisher's exact test (asserting that the response rate in the treatment arm was greater) was calculated. The proportion of simulations that produced p < 0.05 was the estimate of the statistical power for that allocation strategy under those trial parameters. Confidence intervals were calculated using the method of Clopper and Pearson. 27 Values are rounded to two or three significant digits.
Results

Trials using adaptive strategies allocate more patients to efficacious donors
The purpose of adaptive donor allocation strategies is to identify and use efficacious donors. We therefore expected that simulated trials that use adaptive strategies would allocate more patients to efficacious donors (compared to simulated trials that used the block or random donor allocation strategies).
For every parameter set simulated, the average fraction of patients in the treatment arm that were allocated to efficacious donors was greater in the adaptive strategies (urn-based and myopic Bayesian) than in the nonadaptive strategies (block and random; Table S1 ). The two nonadaptive allocation strategies performed almost identically: for each parameter set, their results differed by less than 1 percentage point. The two adaptive strategies performed similarly: for half of the parameter sets, their results differed by less than 2 percentage points. In the remaining parameter sets, their results varied by between 2 and 9 percentage points.
When efficacious donors are common (f eff ¼ 0:9), the adaptive and nonadaptive strategies performed similarly (Figure 2) . In other cases, the performance of the two strategies differed substantially. For example, for the parameterization most similar to the one in Table 1 , the random strategy allocated 15% of patients to efficacious donors while the myopic Bayesian strategy allocated 41% of patients to efficacious donors.
Trials using adaptive allocation have higher statistical power
Because trials that used the adaptive donor allocation strategies allocated more patients to efficacious donors than the trials that used the nonadaptive strategies, and because an equal number of patients were allocated to the placebo arm in both sets of strategies, we expected that trials using adaptive strategies would have greater statistical power.
The adaptive strategies consistently yielded higher statistical powers than the nonadaptive strategies (Table 2) . When efficacious donors are rare, the performance gap is larger. For example, for the parameterization most similar to the one in Table 1 , a trial that uses random allocation is expected to have 9% statistical power, while the myopic Bayesian strategy can deliver 39% statistical power. The gap in performance is smallest when selecting a donor at random is likely to yield an efficacious donor: among the trials with f eff ¼ 0:9, the adaptive and nonadaptive statistical powers differed by less than 6 percentage points.
Low statistical powers when f eff is small are likely due to the fact that if all the available donors are not efficacious, then no allocation strategy should make a trial achieve significance. For example, if only 15% of donors are efficacious (f eff ¼ 0:15) and there are only six donors (the number used in these simulations), then we expect that 38% of trials will have no good donors (using the binomial distribution function). We therefore separately analyzed the simulated trials in which no donors were efficacious and the simulated trials in which at least one donor was efficacious (Table S2) . When no donors are efficacious, trials with adaptive or nonadaptive strategies have $ 0% statistical power. Among trials with at least one efficacious donor, the difference in statistical power between adaptive and nonadaptive strategies is greater than the difference computed using the results of all trials.
Conversely, the statistical power computed in traditional calculations that do not account for differences in donor efficacy (i.e. that assume that all donors are efficacious, or equivalently f eff ¼ 1:0) is, in many cases, Figure 2 . The Bayesian myopic strategy allocates more patients to efficacious donors. For the parameterization most similar to the one in Table 1 (top), the Bayesian myopic heuristic (red) allocated more patients to efficacious donors than random allocation (black) did. When efficacious donors are common (bottom; same parameters as top but with f eff ¼ 0:9), the two strategies allocate similar numbers of patients to efficacious donors. For visual clarity, only trials in which there was at least one efficacious donor are shown. substantially higher than the statistical power computed when accounting for differences in donor efficacy ( Table  2 , column ''Naive power''). For example, for the parameter set most similar to the one in Table 1 , the naive calculation predicts 94% statistical power, but the calculation that accounts for differences in donor efficacy predicts only 9% statistical power for nonadaptive allocation strategies. The differences between the statistical powers computed by the naive method and our approach are largest when f eff is small.
Performance of adaptive strategies depend on their parameterization
In these simulations, we varied the actual values of p pl and p eff but we always initialized the adaptive algorithms the same way. To determine the sensitivity of the adaptive allocation algorithms' performance to their initialization, we simulated trials in which the actual model parameters were fixed but the algorithms' initializations varied (Tables S3 and S4 ). The myopic Bayesian algorithm's performance was mostly robust to the parameterization of its prior distribution except when the prior was strong and inaccurate. Accurate priors, weak priors, and uniform priors provide comparable performance. In contrast, the urn algorithm delivered widely varying statistical powers, from 15 to 40%, depending on its parameterization.
Increasing the number of available donors benefits the adaptive Bayesian strategy
Increasing the number of available donors increases the probability that at least one of them will be efficacious. We therefore determined, for each donor allocation strategy, the number of available donors that optimized the trial's expected statistical power. Simulations showed that increasing the size of the donor ''pool'' almost always Table 2 . Adaptive strategies yield clinical trials with higher statistical power. ''FMT power'' is the statistical power computed by simulating the results of trials that would occur if the frequency of efficacious donors if f eff . ''Naive power'' is the statistical power computed in the situation in which all donors are efficacious (i.e. f eff ¼ 1:0). All 95% confidence intervals on these values are within 1 percentage point of the reported value and are not shown. increased the statistical power of trials using the myopic Bayesian donor allocation but, depending on the parameter set, could increase or decrease the statistical power of trials using other allocation strategies (Table S5) . Table 3 shows how donor selection strategy and model parameter values affect the optimal number of donors. Notably, when efficacious donors are uncommon (f eff ¼ 0:15) and only moderately efficacious (p eff ¼ 0:4), the nonadaptive strategies perform optimally when only one donor is used. In other words, when using nonadaptive strategies in this parameter regime, it is wiser to take the 15% chance of picking a single efficacious donor than it is to distribute patients across many donors, allotting around 15% of them to efficacious donors. In contrast, the myopic Bayesian donor allocation almost always benefits from a larger donor pool.
Discussion
Model limitations
We chose to use a simple model for a simple use case because, in the absence of data about the treatment histories of hundreds of patients using dozens of donors, we do not believe that more complicated models will aid trial design. The model's greatest weakness is that it cannot be validated, but it is exactly the model's purpose to improve the probability of collecting the kind of information that could validate or invalidate it. In light of the dearth of data, we developed a simple model, and it could be that the simplifications we made limit the model's validity. For example, the model assumes that each donor produces efficacious stool or inefficacious stool (when in fact there is probably day-to-day and donor-to-donor variation in stool efficacy) and that all patients receive one course of treatment (while, say, patients who do not respond to a first treatment might be treated with stool from a different donor). As more data about the variability in efficacy between donors emerge, we expect that this model could be validated and improved.
In our formulation of the model, we only considered optimizing the assignment of patients to donors within the treatment arm, thus ''protecting'' the size of the placebo arm. Future work could determine if there is a benefit to adaptively assigning patients to the placebo or treatment arms based on estimations of the donors' quality. We also assumed in our simulations that the outcome from all the previous patients treatments is known before the donor for the next patient is selected. In reality, patients in an FMT trial overlap. The urn-based method can still be used for overlapping patients, 24 but the myopic Bayesian method would require some modification. The urnbased approach is also randomized, which is desirable in clinical trials because it can reduce certain kinds of bias.
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Future work could adapt the myopic Bayesian heuristic, which is deterministic, for adaptive randomization 28 and for delays between patient allocation and outcome observation.
Differences in donor efficacy should be accounted for in trial design
Our results entail recommendations to clinicians. First, the statistical powers we computed here are, in many cases, well below the statistical powers computed assuming that all donors are efficacious. We therefore encourage researchers to consult our predictions about statistical power when deciding on the size of their trials. Second, a high placebo rate can substantially decrease the statistical power of an FMT trial. We therefore encourage researchers to use the most stringent outcome measurement possible (e.g. an endoscopic Mayo score for inflammatory bowel disease).
Third, adaptive donor allocation strategies consistently delivered higher statistical power than traditional, nonadaptive approaches. We therefore recommend that researchers use such an adaptive strategy. The urnbased strategy has the advantages that similar response-adaptive strategies may be familiar to clinicians, it is randomized, and it is simple to implement. However, an urn-based strategy needs to be carefully parameterized: a badly parameterized urn-based strategy performs similarly to random allocation. The adaptive Bayesian donor allocation algorithm performs well even when using the ''default'' settings (a uniform prior) but is complex and deterministic. To fully leverage this strategy, a clinician would need to consult the algorithm's output after every patient outcome and follow the algorithm's deterministic instructions, which might introduce bias.
Fourth, adaptive algorithms benefit from having access to a ''bank'' of 10 or more donors. Researchers hoping to achieve the full benefits of adaptive donor selection must be prepared to change donors multiple times during the trial.
Finally, researchers reporting about FMT trials should include information about the donors, notably how many donors were used and what proportion of patients allotted to each donor responded to treatment. This information will help future researchers account for differences in donor efficacy.
Future research may identify mechanistic explanations of FMT's efficacy
The adaptive allocation strategies we described here have a narrow aim: to increase the number of successful patient outcomes in a trial. In theory, an adaptive trial design is capable of more. For example, if it were hypothesized that FMT succeeded or failed because of the presence or absence of some particular microbial species in the donor's stool, then an adaptive trial design could recommend donor choices that aim to identify that critical species.
We did not pursue a hypothesis-centric approach because we believe it is premature. Even the mechanism by which FMT treats C. difficile, the most well-studied case, remains unclear. We expect that strong hypotheses about mechanism will come from retroactive comparison of efficacious versus inefficacious stool after clinical trials have definitively shown that FMT is effective for treating some disease. Our study aims to do exactly this. Until then, we hope that our results about adaptive donor allocation help more patients benefit from FMT and will help clinicians identify those conditions that FMT can treat.
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